L606

L606 is an investigational, sustained-release, liposomal formulation of treprostinil designed for inhalation via a next-generation nebulizer. It encapsulates the prostacyclin analogue treprostinil within proprietary liposomes to enable controlled release into the lungs, aiming to enhance drug exposure over an extended period and reduce local respiratory tract irritation. The formulation is intended for twice-daily administration and is being developed primarily for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). By providing a more stable pharmacokinetic profile compared to immediate-release formulations like Tyvaso (treprostinil), L606 may improve tolerability and patient outcomes[1][2][3][4][6][7].

Other names

liposomal treprostinil inhalation suspensionliposomal treprostinil inhalation solution